clinical trial · NCT06606340
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
Duchenne Muscular DystrophyEteplirsenGolodirsenCasimersen
brief summary
This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen, golodirsen, and casimersen in routine clinical practice. Participants in this study will have been prescribed eteplirsen, golodirsen, or casimersen commercially prior to entry into the study.
started
Jan 7, 2019
primary completion
Dec 31, 2033
completion
Dec 31, 2033
last updated
Sep 10, 2025
official title
A Long-term Observational Study Evaluating Sarepta Therapeutics, Inc.'s Exon-Skipping Therapies in Patients With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol